Therapeutic horizons for amyotrophic lateral sclerosis

Current Opinion in Neurobiology

Volumn 6, Issue 5, 1996, Pages 679-687

  Rothstein, Jeffrey D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; GABAPENTIN; NEUROTROPHIC FACTOR; RILUZOLE; SOMATOMEDIN C;

AMYOTROPHIC LATERAL SCLEROSIS; CELL TRANSPLANTATION; CHEMOPROPHYLAXIS; HUMAN; MOTOR NEURON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0030273704     PISSN: 09594388     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-4388(96)80103-6     Document Type: Article

References (66)

1. Aran F. Recherches sur une maladie non encore decrite de system musculaire (atrophie musculaire progressive). Arch Gen Med (Paris). 24:1850;4-35. Studies of an as yet undescribed disease of the muscular system (progressive muscular atrophy).
2. Charcot J-M, Joffroy A. Deux cas d'atrophie musculaire progressive. Arch Physiol Norm Pathol. 2:1869;354-367. Two cases of progressive muscular atrophy.
3. Kuncl RW, Crawford TO, Rothstein JD, Drachman DB. Motor neuron diseases. Asbury AK, McKhann GM, McDonald WI. edn 2 Diseases of the Nervous System. 1992;1179-1208 WB Saunders, Philadelphia.
4. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, Oregan JP, Deng H-X, et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
5. Brown RH Jr. Superoxide dismutase and familial amyotrophic lateral sclerosis: new insights into mechanisms and treatments. Ann Neurol. 39:1996;145-146.
6. of special interest Brown RH Jr. Amyotrophic lateral sclerosis recent insights from genetics and transgenic mice. Cell. 80:1995;687-692 A synthesis of various current ideas on the pathogenesis of ALS. The author discusses links among the various proposed mechanisms for chronic motor neuron degeneration.
7. of special interest Rothstein JD. Pathogenesis of ALS: the excitotoxicity hypothesis. Neurology. 1996; A review of the role of excitotoxicity in the pathogenesis of ALS.
8. Appel SH, Engelhardt JI, Garcia J, Stefani E. Immunoglobulins from animal models of motor neuron disease and from amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc Natl Acad Sci USA. 88:1991;647-651.
9. Appel SH, Smith RG, Engelhardt JI, Stefani E. Evidence for autoimmunity in amyotrophic lateral sclerosis. J Neurol Sci. 124:1994;14-19. (suppl).
10. Smith RG, Hamilton S, Hofmann F, Schneider T, Nastainczyk WCS, Birnbaumer L, Stefani E, Appel SH. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med. 327:1992;1721-1728.
11. Smith RG, Alexianu ME, Crawford G, Nyormoi O, Stefani E, Appel SH. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc Natl Acad Sci USA. 91:1994;3393-3397.
12. Rothstein JD, Martin LJ, Kuncl RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 326:1992;1464-1468.
13. Shaw PJ, Chinnery RM, Ince PG. [3H]D-aspartate binding sites in the normal human spinal cord and changes in motor neuron disease: a quantitative autoradiographic study. Brain Res. 655:1994;195-201.
14. Rothstein JD, Jin L, Dykes-Hoberg M, Kuncl RW. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc Natl Acad Sci USA. 90:1993;6591-6595.
15. of special interest Rothstein JD, Dykes-Hoberg M, Pardo CA, Bristol LA, Jin L, Kuncl RW, Kanai Y, Hediger MA, Wang Y, Schielke J, Welty DF. Antisense knockout of glutamate transporters reveals a predominant role for astroglial glutamate transport in excitotoxicity and clearance of extracellular glutamate. Neuron. 16:1996;675-686 This study, largely designed to evaluate the basic physiology of glutamate transporter subtypes, demonstrates that a loss of astroglial, especially GLT-1 (see [19]), glutamate transporters, can lead to neurotoxicity and elevated extracellular glutamate levels.
16. Shaw PJ, Ince PG, Falkous G, Mantle D. Oxidative damage to protein in sporadic motor neuron disease spinal cord. Ann Neurol. 38:1995;691-695.
17. Bowling AC, Schulz JB, Brown RH Jr, Beal MF. Superoxide dismutase activity, oxidative damage, and mitochondrial energy metabolism in familial and sporadic amyotrophic lateral sclerosis. J Neurochem. 61:1993;2322-2325.
18. of special interest Cleveland DW. Neuronal growth and death: order and disorder in the axoplasm. Cell. 84:1996;663-666 The author provides a concise review of neurofilament biology and how neurofilament abnormalities could contribute to motor neuron disease.
19. of special interest Rothstein JD, Van Kammen M, Levey AI, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol. 38:1995;73-84 Some sporadic ALS patients appear to have a loss of glutamate transport activity in neuropathologically affected brain regions [12]. These changes were not seen in disease controls, including Alzheimer's and Huntington's disease patients. This study demonstrates that the functional defects in glutamate transport demonstrated in [12] are probably attributable to a selective loss of the astroglial glutamate transporter GLT-1 and not to the other astroglial transporter GLAST or the neuronal glutamate transporter EAAC1.
20. Rothstein JD, Tsai G, Kuncl RW, Clawson L, Cornblath DR, Drachman DB, Pestronk A, Stauch BL, Coyle JT. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol. 28:1990;18-25.
21. Shaw PJ, Forest V, Ince PG, Richardson JP, Wastell HJ. CSF and plasma amino acid levels in motor neuron disease - elevation of CSF glutamate in a subset of patients. Neurodegeneration. 4:1995;209-216.
22. Lin G, Bristol LA, Rothstein JD. An abnormal mRNA leads in downregulation of glutamate transporter EAAT2 (GLT-1) expression in familial amyotrophic lateral sclerosis. Ann Neurol. 40:1996;540-541.
23. of outstanding interest Gurney ME, Cuttings FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 39:1996;147-157 The first clinical trials of SOD1 transgenic mice. Anti-glutamate (riluzole and gabapentin) drugs and the antioxidant vitamin E were studied and found to alter the course of the disease in these mice. Notably, the antioxidants delayed disease onset but not overall survival of the mice,; whereas the antiglutamates did not alter disease onset, but slightly increased survival. This paper suggests that both initiating and propagating processes may occur in ALS.
24. of outstanding interest Wong PC, Pardo CA, Borchelt DR, Lee MK, Copeland NG, Jenkins NA, Sisodia SS, Cleveland DW, Price DL. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116 A detailed study of transgenic mice carrying a different SOD1 mutation, G37R, from the one studied by Gurney et al [23]. The authors provide a detailed neuropathological and biochemical evaluation of the progression of the disease in these mice. Similar to this study by Gurney et al. [23], this study confirms the selective motor neuron degeneration associated with a SOD1 mutation. The G37R mutation appears to cause a vacuolar-type degeneration. Furthermore, the authors suggest that the toxicity associated with the SOD1 mutation confirms a gain-of-adverse property, rather than a simple loss of function.
25. Lee MK, Marszalek JR, Cleveland DW. A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron. 13:1994;975-988.
26. Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell. 73:1993;23-33.
27. of special interest Pardo CA, Xu Z, Borchelt DR, Price DL, Sisodia SS, Cleveland DW. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. Proc Natl Acad Sci USA. 92:1995;954-958 The first detailed study of the distribution of SOD1 in the CNS. The authors demonstrate the relatively ubiquitous localization of SOD1 to neurons and glia.
28. Leigh PN, Swash M. Cytoskeletal pathology in motor neuron disease. Adv Neurol. 56:1991;115-125.
29. Lowe J. New pathological findings in amyotrophic lateral sclerosis. J Neurol Sci. 124:1994;38-51. (suppl).
30. Yamauchi H, Fukuyama H, Ouchi Y, Nagahama Y, Kimura J, Asato R, Konishi J. Corpus callosum atrophy in amyotrophic lateral sclerosis. J Neurol Sci. 134:1995;189-196.
31. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
32. Patel M, Day BJ, Crapo JD, Fridovich I, McNamara JO. Requirement for superoxide in excitotoxic cell death. Neuron. 15:1996;345-355.
33. Beal MF. Role of excitotoxicity in human neurological disease. Curr Opin Neurobiol. 2:1992;657-662.
34. Volterra A, Trotti D, Tromba C, Floridi S, Racagni G. Glutamate uptake inhibition by oxygen free radicals in rat cortical astrocytes. J Neurosci. 14:1994;2924-2932.
35. Trotti D, Rossi D, Gjesdal O, Levy LM, Racagni G, Danbolt NC, Volterra A. Peroxynitrite inhibits glutamate transporter subtypes. J Biol Chem. 271:1996;5976-5979.
36. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738.
37. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol. 38:1995;357-366.
38. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, Alexander DD, Caliendo J, Hentati A, Kwon YW, Deng H-X, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 264:1994;1772-1775.
39. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 330:1994;585-591.
40. of outstanding interest Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 347:1996;1425-1431 In this dose-ranging follow-up study (see [39]), the beneficial effect of riluzole in ALS was confirmed. In spite of this success, perplexing questions still remain. If patients lived longer, why did the drug not alter their decline in motor strength and pulmonary function?
41. Przedborski S, Donaldson D, Janowec M, Kish SJ, Guttman M, Rosoklija G, Hays AP. Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis. Ann Neurol. 39:1996;158-165.
42. Rothstein JD, Bristol LA, Hosler B, Brown RH Jr, Kuncl RW. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci USA. 91:1994;4155-4159.
43. of special interest Rothstein JD, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem. 65:1995;643-651 Demonstrates the potential value of using cell culture models to screen potential neuroprotective agents.
44. Miller RG, Gelinas D, Moore D, Mendoza M, Quien A, Young L, Armon C, Linda L, Barohn R, Bryan W, et al. A placebo-controlled trial of gabapentin in amyotrophic lateral sclerosis. Neurology. 1996;. in press.
45. of special interest. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology. 46:1996;1244-1249 The results from one of the largest ALS trials to date, which revealed no beneficial effect for CNTF in slowing motor decline. Side effects of the recombinant protein were significant and led to a limitation of dosing.
46. Miller RG, Petajan JH, Bryan WW, Armon C, Barohn RJ, Goodpasture JC, Hoagland RJ, Parry GJ, Ross MA, Stromatt SC. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol. 39:1996;256-260.
47. Price DL, Cleveland DW, Koliatsos VE. Motor neuron disease and animal models. Neurobiol Dis. 1:1994;3-11.
48. Clatterbuck PE, Price DL, Koliatsos VE. Ciliary neurotrophic factor prevents retrograde neuronal death in the adult central nervous system. Proc Natl Acad Sci USA. 90:1993;2222-2226.
49. Sendtner M, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. Nature. 345:1990;440-441.
50. Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simpson LC, Moffet B, Vandlen RA, Koliatsos VE, Rosenthal A. GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. Science. 266:1994;1062-1064.
51. Yan Q, Elliott J, Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death. Nature. 360:1992;753-755.
52. Koliatsos VE, Price WL, Pardo CA, Price DL. Ventral root avulsion: an experimental model of death of adult motor neurons. J Comp Neurol. 342:1994;35-44.
53. Sendtner M, Holtmann B, Kolbeck R, Thoenen H, Barde Y-A. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature. 360:1992;757-759.
54. Yan Q, Matheson C, Lopez OT. In vivo neurotrophic effects of GDNF on neonatal and adult facial motor neurons. Nature. 373:1995;341-344.
55. Mitsumoto H, Ikeda K, Holmlund T, Greene T, Cedarbaum JM, Wong V, Lindsay RM. The effects of ciliary neurotrophic factor of motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol. 36:1994;142-148.
56. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science. 265:1994;1107-1110.
57. Sendtner M, Schmalbruch H, Stöckli KA, Carroll P, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature. 358:1992;502-504.
58. Sagot Y, Tan SA, Hammang JP, Aebischer P, Kato AC. GDNF slows loss of motoneurons but not axonal degeneration or premature death of pmn/pmn mice. J Neurosci. 16:1996;2335-2341.
59. Fournier J, Steinberg R, Gauthier T, Keane PE, Guzzi U, Coude FX, Bougault I, Maiffrand JP, Soubrie P, Le Fur G. Protective effects of SR57746A in central and peripheral models of neurodegenerative disorders in rodents and primates. Neuroscience. 55:1993;629-641.
60. Drachman DB, Chaudhry V, Cornblath D, Kuncl RW, Pestronk A, Clawson L, Mellits ED, Quaskey S, Quinn T, Calkins A, Order S. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol. 35:1994;142-150.
61. Koh JY, Gwang BJ, Lobner D, Choi DW. Potentiated necrosis of cultured cortical neurons by neurotrophins. Science. 268:1995;573-575.
62. Fernandez-Sanchez MT, Novelli A. Basic fibroblast growth factor protects cerebellar neurons in primary culture from NMDA and non-NMDA receptor mediated neurotoxicity. FEBS Lett. 335:1993;124-131.
63. Gwang BJ, Koh JY, Chen M, Dugan LL, Behrens MM, Lobner D, Choi DW. BDNF or IGF-1 potentiates free radical mediated injury in cortical cell culture. Neuroreport. 7:1995;93-96.
64. Conover JC, Erickson JT, Katz DM, Bianchi LM, Poueymirou WT, McClain J, Pan L, Helgren M, Ip NY, Boland P, et al. Neuronal deficits, not involving motor neurons, in mice lacking BDNF and/or NT4. Nature. 375:1995;235-238.
65. Takahashi R, Yokoji H, Misawa H, Hayashi M, Hu J, Deguchi T. A null mutation in the human CNTF gene is not causally related to neurological diseases. Nature Genet. 7:1994;79-84.
66. Louwerse ES, Weverling GJ, Bossuyt PMM, Meyjes FEP, Dejong JMBV. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol. 52:1995;559-564.